HIMS · Hims & Hers Health, Inc.
AI read · Neutral
The AI's read
A rating is one firm's view, not a change to Hims & Hers' sales, costs, or products. The story gives no new company results or business developments, so a neutral reading fits.
Hims & Hers received a reaffirmed Hold rating and a $21 price target from BofA. This is an analyst's view, not a reported change in the company's business, so its outlook stays unchanged.
A rating is one firm's view, not a change to Hims & Hers' sales, costs, or products. The story gives no new company results or business developments, so a neutral reading fits.
Follow Hims & Hers Health, Inc. (HIMS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HIMS